稳心颗粒加曲美他嗪治疗病毒性心肌炎的临床研究

Efficacy and safety of Wenxinkeli plus trimetazidine in treatment of viral myocarditis

目的观察稳心颗粒加曲美他嗪治疗病毒性心肌炎的临床疗效及安全性。方法将45例患者随机均分为两组。治疗组给予稳心颗粒（每日5g／3次，温水冲服）治疗、曲美他嗪20mg3／日，对照组给予三磷酸腺苷、辅酶A、维生素C、辅酶Q10等营养心肌的药物，两组疗程均为4周。结果治疗组临床症状、体征及心电图改善、心肌酶恢复优于对照组，差异有统计学意义（P〈0．05）。结论稳心颗粒治疗病毒性心肌炎室性早搏疗效确切，且无明显不良反应，安全性好。

Objective To observe clinical efficacy and safety of Wenxinkeli plus trimetazidine in treatment of viral myocarditis. Methods Totally 45 patients with viral myocarditis were randomly divided into two groups. Patients in treatment group were given orally Wenxinkeli 5 g, 3 times a day and trimetazidine, 20 mg, 3 times a day, and the patients in control group were given adenosine triphosphate, coenzyme A,vitamin C,coenzyme QIO etc. ; the treatments persisted for 4 weeks for both groups. Results The clinical symptoms, signs, ECG improvement, and restoration of myocardial enzyme were significantly better than those of the control group （P 〈 0.05）. Conclusions Wenxinkeli plus trimetazidine was effective in treatment of ventricular premature contractions of viral myocarditis, and showed no significant adverse reactions.